<DOC>
	<DOC>NCT00318500</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in reproductive aged women.</brief_summary>
	<brief_title>Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<criteria>Surgical diagnosis of endometriosis within the last 10 years Sexually active, nonpregnant, nonlactating women (1845 years) with regular menstrual cycles who are willing to use nonhormonal contraception Conditions requiring the use of chronic pain therapy Prophylactic use of analgesics to avoid endometriosisrelated pain</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>Dysmenorrhea</keyword>
	<keyword>Pelvic pain</keyword>
	<keyword>Dyspareunia</keyword>
</DOC>